The effect of hepatic impairment on outcomes in phase I clinical trials in cancer subjects

AS Mansfield, MA Rudek, D Vulih, GL Smith… - Clinical Cancer …, 2016 - AACR
Abstract Purpose: The NCI Cancer Therapy Evaluation Program sponsors hepatic
dysfunction phase I clinical trials (HDCT) and phase 1 clinical trials (P1CT) to determine safe …
被引用次数：22 相关文章
[HTML] nih.gov

[HTML][HTML] The effect of hepatic impairment on outcomes in phase 1 clinical trials in cancer subjects

AS Mansfield, MA Rudek, D Vulih… - … cancer research: an …, 2016 - ncbi.nlm.nih.gov
Purpose The NCI Cancer Therapy Evaluation Program sponsors hepatic dysfunction phase
1 clinical trials (HDCT) and phase 1 clinical trials (P1CT) to determine safe doses and …

The effect of hepatic impairment on outcomes in phase I clinical trials in cancer subjects

NCI Organ Dysfunction Working … - Clinical Cancer …, 2016 - pure.johnshopkins.edu
Purpose: The NCI Cancer Therapy Evaluation Program sponsors hepatic dysfunction phase
I clinical trials (HDCT) and phase 1 clinical trials (P1CT) to determine safe doses and …

The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects

AS Mansfield, MA Rudek, D Vulih… - … : an official journal …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose The NCI Cancer Therapy Evaluation Program sponsors hepatic dysfunction phase I
clinical trials (HDCT) and phase 1 clinical trials (P1CT) to determine safe doses and …

The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects.

AS Mansfield, MA Rudek, D Vulih, GL Smith… - … Cancer Research: an …, 2016 - europepmc.org
Purpose The NCI Cancer Therapy Evaluation Program sponsors hepatic dysfunction phase I
clinical trials (HDCT) and phase 1 clinical trials (P1CT) to determine safe doses and …

The effect of hepatic impairment on outcomes in phase I clinical trials in cancer subjects

NCI Organ Dysfunction Working … - Clinical Cancer …, 2016 - mayoclinic.elsevierpure.com
Purpose: The NCI Cancer Therapy Evaluation Program sponsors hepatic dysfunction phase
I clinical trials (HDCT) and phase 1 clinical trials (P1CT) to determine safe doses and …